Predictive Oncology’s (NASDAQ: POAI) Subsidiary Refining, Strengthening Personalized Oncology Approach to Ovarian Cancer
- Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of female reproductive system
- TumorGenesis can provide pharmaceutical companies newfound ability for more effective, expeditious drug development
- Company is global developer of world-class, innovative technologies using 3D cell culture, media
In the treatment of cancer, most patients receive standard one-size-fits-all drug treatments identified from studying the cancers, treatments and results of other patients. In the evolving world of personalized oncology, the approach entails testing a variety of potential drugs on a patient’s unique tumor to discover which drug, or combination of drugs, might work best. That is precisely the approach that Predictive Oncology (NASDAQ: POAI), through its subsidiary TumorGenesis, takes in addressing ovarian cancer.
According to the American Cancer Society, ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system (https://nnw.fm/9lYb7). The ACS estimated that in 2021, more than 21,000 women will be diagnosed with ovarian cancer, with more than 13,000 women dying from it.
The standard of care for ovarian cancer patients is the use of cisplatin, or carboplatin, in combination with taxol in alternating treatments following surgery weekly with intraperitoneal and intravenous infusions of the two different drugs, one IV and the other IP, then alternating; only 40–50% of patients survive past five years (https://nnw.fm/xiK3v). TumorGenesis, through its proprietary TumorGenesis tumor modeling, is confident it can provide pharmaceutical companies newfound ability for more effective and expeditious drug development and, as a result, improve patient outcomes.
That’s a lofty claim, but one that TumorGenesis can back up with its innovative personalized oncology approach. The company is a global developer of world-class and innovative technologies using 3D cell culture and media; the company specializes in technology that preserves a patient’s unique cancer tissue biological signatures, thereby allowing researchers to study cancer in the laboratory using cancer samples that reflect the actual tumors found in a patient.
This idea of personalized oncology isn’t unique to TumorGenesis; however, personalized oncology has been generally unsuccessful in the past because cell lines can only be established from less than 1% of all ovarian cancers. TumorGenesis technology enables cell lines from patients to represent more than 90% of patient tumors that the current 1% of ovarian cancer cells available for research don’t represent — numbers that are transformative for ovarian cancer patient treatments.
The result, simply stated, assists health providers in selecting the most effective drug to treat a specific patient’s unique cancer — personalized medicine at its finest.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of more than 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of female reproductive system
- TumorGenesis can provide pharmaceutical companies newfound ability for more effective, expeditious drug development
- Company is global developer of world-class, innovative technologies using 3D cell culture, media
In the treatment of cancer, most patients receive standard one-size-fits-all drug treatments identified from studying the cancers, treatments and results of other patients. In the evolving world of personalized oncology, the approach entails testing a variety of potential drugs on a patient’s unique tumor to discover which drug, or combination of drugs, might work best. That is precisely the approach that Predictive Oncology (NASDAQ: POAI), through its subsidiary TumorGenesis, takes in addressing ovarian cancer.
According to the American Cancer Society, ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system (https://nnw.fm/9lYb7). The ACS estimated that in 2021, more than 21,000 women will be diagnosed with ovarian cancer, with more than 13,000 women dying from it.
The standard of care for ovarian cancer patients is the use of cisplatin, or carboplatin, in combination with taxol in alternating treatments following surgery weekly with intraperitoneal and intravenous infusions of the two different drugs, one IV and the other IP, then alternating; only 40–50% of patients survive past five years (https://nnw.fm/xiK3v). TumorGenesis, through its proprietary TumorGenesis tumor modeling, is confident it can provide pharmaceutical companies newfound ability for more effective and expeditious drug development and, as a result, improve patient outcomes.
That’s a lofty claim, but one that TumorGenesis can back up with its innovative personalized oncology approach. The company is a global developer of world-class and innovative technologies using 3D cell culture and media; the company specializes in technology that preserves a patient’s unique cancer tissue biological signatures, thereby allowing researchers to study cancer in the laboratory using cancer samples that reflect the actual tumors found in a patient.
This idea of personalized oncology isn’t unique to TumorGenesis; however, personalized oncology has been generally unsuccessful in the past because cell lines can only be established from less than 1% of all ovarian cancers. TumorGenesis technology enables cell lines from patients to represent more than 90% of patient tumors that the current 1% of ovarian cancer cells available for research don’t represent — numbers that are transformative for ovarian cancer patient treatments.
The result, simply stated, assists health providers in selecting the most effective drug to treat a specific patient’s unique cancer — personalized medicine at its finest.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of more than 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
